Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Elanco Animal Health turns veterinary science into revenue isn’t easy—each 10-K details dozens of R&D pipeline assets, FDA approvals, and integration costs from the Bayer Animal Health acquisition. If you have ever asked, “Where can I read Elanco’s quarterly earnings report 10-Q filing?” or “How do I locate Elanco insider trading Form 4 transactions?” you already know the challenge.
Stock Titan solves it. Our AI-powered summaries translate the technical language in every Elanco SEC document into plain English, flagging segment margins, companion-animal growth, and farm-animal productivity trends. Receive real-time alerts the moment an Elanco Form 4 insider transactions real-time filing hits EDGAR, or open an Elanco 8-K material events explained card to see if a new parasiticide received FDA approval—all without wading through hundreds of pages.
Here’s what you can explore in seconds:
- Elanco annual report 10-K simplified—AI highlights pipeline updates, manufacturing efficiencies, and acquisition synergies.
- Elanco quarterly earnings report 10-Q filing—compare sequential companion-animal sales and R&D spend.
- Elanco proxy statement executive compensation—see how leadership incentives align with product launch milestones.
- Elanco executive stock transactions Form 4—monitor insider buying ahead of material announcements.
Whether you search “understanding Elanco SEC documents with AI” or need fast Elanco earnings report filing analysis, our platform keeps every filing type in one place, updated the moment Elanco submits it. Save hours, spot trends early, and make better calls on ELAN.
Elanco Animal Health (ELAN): Schedule 13G filing shows BlackRock, Inc. reported beneficial ownership of 44,021,766 shares of common stock, representing 8.9% of the class as of 09/30/2025. BlackRock reports sole voting power over 42,268,742 shares and sole dispositive power over 44,021,766 shares, with no shared voting or dispositive power.
BlackRock filed as a parent holding company (HC) and certified the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Elanco. The filing notes that various persons have rights to dividends or sale proceeds through managed accounts, and no single person’s interest exceeds five percent of total outstanding common shares.
Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), reported a Section 16 transaction dated
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), reported on
Elanco Animal Health Inc. (ELAN) reported insider awards to Executive Vice President and Chief Financial Officer Robert M. VanHimbergen. The Form 4 discloses a grant of 109,857 restricted stock units that vest in three equal tranches on July 7, 2026, July 7, 2027, and July 7, 2028. The filing also shows a grant of 53,869 employee stock options with an exercise price of $20.80, exercisable beginning in the same three-tranche schedule and expiring on October 1, 2035. Both holdings are reported as direct ownership following the transactions. The Form 4 was signed by an attorney-in-fact on behalf of Mr. VanHimbergen and lists the transaction date as October 1, 2025.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc (ELAN), reported an acquisition of 144.2313 deferred stock units on 09/19/2025. Each deferred stock unit represents the right to one share of common stock or the cash equivalent and settles in cash or shares under the company’s Executive Deferral and Stock Match Plan. The reported transaction used transaction code A (acquisition) at an indicated underlying price of $19.20 per share, and following the transaction Mr. Simmons beneficially owns 17,836.142 shares directly. The Form 4 was signed on behalf of Mr. Simmons by Amy C. Seidel as attorney-in-fact on 09/23/2025.
Rajeev A. Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), acquired 73.6781 deferred stock units on 09/19/2025 under the companys Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent, and such units settle in cash or shares following termination of employment or in a specified future year. After the reported transaction Mr. Modi beneficially owned 6,964.7245 units (directly).
The units were reported with an indicated price of $19.20 per underlying share. The filing was signed by an attorney-in-fact on behalf of Mr. Modi and notes his officer role; no other material transactions or additional context are included.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), acquired 150.2572 deferred stock units on 09/05/2025 at an attributable price of $18.43 each. Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent, and these units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Following this transaction, Mr. Simmons' beneficial ownership is reported as 17,691.9107 shares (direct). The Form 4 was signed by an attorney-in-fact on 09/09/2025. No other cash purchases, sales, or derivative exercises are reported in this filing.
Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation at Elanco Animal Health Inc. (ELAN), reported a Section 16 transaction on 09/05/2025. The filing records an acquisition of 76.7564 deferred stock units (DSUs) at an indicated price of $18.43 per unit. Each DSU represents the right to receive one share of common stock or the cash equivalent and DSUs settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan. The report shows 6,891.0464 shares beneficially owned following the transaction. The Form 4 was signed by Amy C. Seidel as attorney-in-fact on 09/09/2025.
Jeffrey N. Simmons, President, CEO and Director of Elanco Animal Health Inc. (ELAN), reported an acquisition on 08/22/2025 of 154.6198 deferred stock units. Each deferred stock unit represents the right to one share of common stock or a cash equivalent and the units were priced at $17.91 per underlying share for reporting purposes. Following the reported transaction, Mr. Simmons beneficially owned 17,541.6535 shares (or economic equivalents) of Elanco common stock. The deferred stock units will settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan. The Form 4 was signed on behalf of Mr. Simmons by an attorney-in-fact on 08/26/2025.
Elanco Animal Health insider transaction: The Form 4 reports that Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, was granted 78.9849 deferred stock units on 08/22/2025. Each deferred stock unit represents the right to receive one share of Elanco common stock or a cash equivalent. The filing shows an exercise/reference price of $17.91 and indicates Mr. Modi beneficially owns 6,814.29 shares (or units) following the reported transaction. The deferred units will settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
